Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/120599
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studies |
Author: | Martinello, M. Hellard, M. Shaw, D. Petoumenos, K. Applegate, T. Grebely, J. Yeung, B. Maire, L. Iser, D. Lloyd, A. Thompson, A. Sasadeusz, J. Haber, P. Dore, G.J. Matthews, G.V. |
Citation: | Antiviral Therapy, 2016; 21(5):425-434 |
Publisher: | International Medical Press |
Issue Date: | 2016 |
ISSN: | 1359-6535 2040-2058 |
Statement of Responsibility: | Marianne Martinello, Margaret Hellard, David Shaw, Kathy Petoumenos, Tanya Applegate, Jason Grebely, Barbara Yeung, Laurence Maire, David Iser, Andrew Lloyd, Alexander Thompson, Joe Sasadeusz, Paul Haber, Gregory J Dore, Gail V Matthews |
Abstract: | Individuals with recent HCV infection may benefit from shortened duration therapy. These studies evaluated the efficacy and safety of response-guided regimens with pegylated interferon-α2a and ribavirin for people with recent HCV infection.Participants with recent hepatitis C (duration of infection ≤18 months) enrolled in the ATAHC II (pegylated interferon-α2a ± ribavirin) and DARE-C I (pegylated interferon-α2a, ribavirin and telaprevir) studies were included for analysis. Treatment duration was response-guided (ATAHC II: 8, 16, 24 or 48 weeks; DARE-C I: 8, 12 or 24 weeks) and dependent on time to first undetectable HCV RNA using Roche Taqman HCV RNA testing. The primary efficacy end point was sustained virological response at 12 weeks (SVR12) by intention-to-treat. Logistic regression analyses were used to identify predictors of SVR.A total of 82 participants (62% HIV-positive) were enrolled in ATAHC II (treated, n=52) and 14 (79% HIV-positive) in DARE-C I. The predominant modes of HCV acquisition were injecting drug use (ATAHC II 55%, DARE-C I 36%) and sexual intercourse with a partner of the same sex (ATAHC II 39%, DARE-C I 64%). SVR12 was 71% in both ATAHC II (37/52) and DARE-C I (10/14) with 56% in ATAHC II receiving shortened therapy (8 or 16 weeks). SVR was associated with a rapid virological response (odds ratio 10.80; P=0.001).The majority of participants were able to receive short duration response-guided therapy with pegylated interferon-α2a and ribavirin. Response-guided therapy for recent hepatitis C infection could be considered in the absence of available interferon-free therapies. ClinicalTrials.gov registry (ATAHC II: NCT01336010; DARE-C I: NCT01743521). |
Keywords: | Humans Hepatitis C Hepatitis C, Chronic Polyethylene Glycols Oligopeptides Interferon-alpha Recombinant Proteins RNA, Viral Ribavirin Antiviral Agents Treatment Failure Drug Therapy, Combination Drug Administration Schedule Prospective Studies Time Factors Adult Middle Aged Female Male Medication Adherence |
Rights: | Copyright (c) 2016 International Medical Press, all rights reserved. |
DOI: | 10.3851/IMP3035 |
Published version: | http://dx.doi.org/10.3851/imp3035 |
Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.